Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Michael T Meister; Sandra Voss; Dirk Schwabe

doi:10.1002/pbc.25621

Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Michael T Meister
, Sandra Voss
, Dirk Schwabe

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

16 Citaten (Scopus)

Samenvatting

Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.

Originele taal-2	Engels
Pagina's (van-tot)	2018-20
Aantal pagina's	3
Tijdschrift	Pediatric blood & cancer
Volume	62
Nummer van het tijdschrift	11
DOI's	https://doi.org/10.1002/pbc.25621
Status	Gepubliceerd - nov 2015
Extern gepubliceerd	Ja

Toegang tot document

10.1002/pbc.25621

Citeer dit

@article{c947ed4a6f104bd8bbd560ae765de147,

title = "Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab",

abstract = "Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/administration \& dosage, Ataxia Telangiectasia/complications, Brentuximab Vedotin, Cyclophosphamide/administration \& dosage, Epstein-Barr Virus Infections/complications, Herpesvirus 4, Human, Hodgkin Disease/complications, Humans, Immunoconjugates/administration \& dosage, Male, Prednisone/administration \& dosage, Procarbazine/administration \& dosage, Remission Induction, Rituximab/administration \& dosage, Vincristine/administration \& dosage, Young Adult",

author = "Meister, \{Michael T\} and Sandra Voss and Dirk Schwabe",

note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = nov,

doi = "10.1002/pbc.25621",

language = "English",

volume = "62",

pages = "2018--20",

journal = "Pediatric blood \& cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

AU - Meister, Michael T

AU - Voss, Sandra

AU - Schwabe, Dirk

PY - 2015/11

Y1 - 2015/11

N2 - Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.

AB - Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Ataxia Telangiectasia/complications

KW - Brentuximab Vedotin

KW - Cyclophosphamide/administration & dosage

KW - Epstein-Barr Virus Infections/complications

KW - Herpesvirus 4, Human

KW - Hodgkin Disease/complications

KW - Humans

KW - Immunoconjugates/administration & dosage

KW - Male

KW - Prednisone/administration & dosage

KW - Procarbazine/administration & dosage

KW - Remission Induction

KW - Rituximab/administration & dosage

KW - Vincristine/administration & dosage

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84942191762

U2 - 10.1002/pbc.25621

DO - 10.1002/pbc.25621

M3 - Article

C2 - 26109475

SN - 1545-5009

VL - 62

SP - 2018

EP - 2020

JO - Pediatric blood & cancer

JF - Pediatric blood & cancer

IS - 11

ER -

Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit